Temple, the wearable device startup founded by former Eternal CEO Deepinder Goyal, is facing mounting scrutiny from medical professionals over its scientific claims, with Goyal taking to social media platform X on 6 November 2026 to publicly defend the product and reject allegations that it misleads consumers. The dispute has ignited a wider debate over the validation standards that consumer wellness devices should meet before making health-related assertions.

Goyal's Defence: Investment, Reputation and a Return Policy

In a series of posts on X, Goyal argued that Temple's claims would be rapidly tested by real users once the device reaches customers, pointing to a 14-day no-questions-asked return policy as a practical safeguard. He disclosed that Temple has invested approximately $30 million in developing the wearable — around $20 million of which is his own capital — contending that the scale of financial commitment is inconsistent with any intent to defraud. Goyal, who said he stepped away from his role as CEO of Eternal specifically to focus on Temple, maintained that his personal and professional reputation is directly tied to the accuracy of the science underpinning the product.

Key Concession: Not All Metrics Clinically Validated Yet

Notably, Goyal acknowledged that Temple has not yet clinically validated all of its metrics, stating that the company would disclose such validation as it becomes available. 'Temple is a fitness tracker and wellness device. We are not a medical device,' he said, adding that further scientific validation and independent studies would follow once the product is in users' hands. The company has committed to publishing validation data on an ongoing basis.

The Doctors' Challenge: Brain Metrics Under the Microscope

The criticism has been led by hepatologist Cyriac Abby Philips, widely known online as The Liver Doc, who has publicly questioned whether Temple's device can legitimately assess brain-related metrics through measurements taken from the superficial temporal artery. In posts on X, Philips alleged that the company has not furnished sufficient evidence to support claims related to brain blood flow and other advanced metrics. He argued that existing public material and pre-print research papers do not conclusively establish the device's stated capabilities, and accused Temple of overstating its scientific foundation. Critics, including Philips, have called for independent, peer-reviewed evidence before such claims gain wider acceptance.

A Broader Debate on Wellness Device Standards

The exchange has triggered a significant discussion on social media around the regulatory and ethical standards governing consumer wellness wearables in India. This comes amid a global trend of health-tech startups launching devices that occupy a grey area between fitness trackers and medical instruments — often making ambitious claims before peer-reviewed validation is complete. India currently lacks a unified framework mandating pre-market clinical validation for wellness wearables that stop short of medical device classification. Notably, Temple's own framing — positioning itself as a fitness and wellness product rather than a medical device — is a common industry strategy to remain outside regulatory purview while still making health-adjacent claims.

What Happens Next

Goyal has indicated that independent studies and further validation data will be released as the product reaches consumers. Critics, however, argue that this sequence — market launch first, validation later — reverses the standard expected of devices making health-related claims. The outcome of this public dispute could influence how Indian regulators and consumers assess the next wave of health-tech wearables entering the market.